Glucosylceramide synthase (GCS or GlcT-1), converting ceramide to glucosylceramide, is a key enzyme for the synthesis of glycosphingolipids. Due to its diverse roles in physiology and diseases, GCS may be a disease marker and drug target. Current assays for enzymes including GCS are based on reactions conducted in a test tube using enzyme preparations. Measurement of enzyme activity in laboratory-made conditions cannot directly evaluate the role of GCS in cells.
INTRODUCTION

Glucosylceramide synthase (GCS) (UDP-glucose ceramide glucosyltransferase, UGCG or
GlcT-1) is a key enzyme for the synthesis of glycosphingolipids (GSLs) (1) (2) (3) . GCS (EC2. 41.80) transfers glucose residues of UDP-glucose to ceramide (Cer) and produces glucosylceramide (GlcCer) (1) . Cer glycosylation by GCS is the first and limited step for GSL synthesis and GlcCer serves as a core structure for more than 300 glycolipids in vertebrates (1, 4, 5) . GSLs are highly located in GSL-enriched microdomains (GEMs) and rafts of membrane; these play crucial roles in the properties and biological functions of cells (6, 7) . In addition to their roles as building blocks of membranes, GSLs modulate signal transduction and cell adhesion; GSLs are involved in cell proliferation, differentiation, immuno-response and oncogenic transformation (8) (9) (10) (11) . Inhibition of GCS, decreasing GlcCer accumulation, is a treatment option for Gaucher's disease (12) . Cer, as a lipid second messenger, mediates many cell-stress responses in embryo development and in tumorigenesis (3, (13) (14) (15) . Cer-induced apoptosis is correlated to the efficacy of anticancer regimens, such as anthracyclines, taxanes, Vinca alkaloid, TNF-α and irradiation (16) (17) (18) . Recent studies indicate that a enhanced expression of GCS is a cause of cancer drug resistance (19) (20) (21) and diabetic insulin resistance (22, 23) . Inhibition of Cer glycosylation on GCS is a therapeutic approach to improve treatments for cancer (16, 20) and type II diabetes (23) .
GCS measurement is essential for evaluating the role of Cer glycosylation in cell functions and for monitoring therapeutic efficiency. After Basu's work (1) , several additional methods have been reported (24) (25) (26) (27) . Employing UDP- [ 3 H]glucose to track glucose transferring has significantly increased the sensitivity of enzyme measurement and characterized the role of GCS in cancer drug resistance (25, 28, 29) . (19) . Cells were maintained in RPMI-1640 medium (Invitrogen) with supplement of 10% fetus bovine serum (FBS), 100 units/ml penicillin, 100 µg/ml streptomycin, 584 mg/liter L-glutamine. Geneticin (G-418, 400 µg/ml) was added to by guest, on August 15, 2017 www.jlr.org
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above culture medium for NCI/ADR-RE/GCS and NCI/ADR-RE/asGCS cells. Cells were cultured in an incubator humidified with 95% air and 5% CO 2 at 37°C.
Western blot
It was carried out as described previously (19) . Briefly, cells (2 x 10 6 cells/100-mm dish) were grown in 10% culture medium for 48 hr and harvested using NP40 cell lysis buffer (Biosource, Camarillo, CA). Equal amount of proteins (50 µg/lane) were resolved using 4-20% gradient SDS-PAGE (Invitrogen). The transferred blots were blocked with 5% fat-free milk PBS (phosphate-buffered saline) and immuno-blotted with anti-GCS serum at 1:500 dilution, at 4°C
for overnight. The antigen-antibody in blots was detected by using secondary antibodyconjugated HRP and enzyme-linked chemiluminescence plus substrate (GE Healthcare). The amount of protein was measured using the bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL) with BSA as a standard.
Immunohistochemistry
Cells (10,000 cells/chamber) were grown in 4-chamber slide with 10% FBS culture medium for 48 hr. After methanol fixation, slides were blocked and then incubated with anti-GCS serum 
Cellular Cer glycosylation assay
The assays were performed as described previously with modification (21, 26, 30) . Briefly, Cells (5 x 10 5 cells/well) were grown 24 hr in 6-well plates with 10% FBS RPMI-1640 medium.
To inhibit GCS enzyme, NCI/ADR-RE cells were exposed to D-threo-PDMP (2.5 and 10 µM) in 5% FBS RPMI-1640 medium for 4 hr at 37ºC. Cells were switched to 500 µl of 1% BSA RPMI-1640 medium containing 500 µM NBD C6-Cer complexed to BSA (equal to 100 µM NBD C6- To distinguish GalCer and GlcCer, the borate-impregnated plates were prepared, as described previously (33, 34) . After spraying 1% aqueous sodium tetraborate, the HPTLC plates were activated at 120 ºC for 30 min. Glycosphingolipids on the borate-impregnated plates were resolved with the solvent system of chloroform/methanol/water (100:30:4, v/v/v). Fluorescent
GalCer, GlcCer and Cer were identified and measured as described above. Anisaldehyde was used for chemical detection of lipids on the borate-impregnated plates (33) .
Tumor-bearing mice and MBO-asGCS treatments
All animal experiments were approved by the Animal Care and Use Committee of the To analyze Cer glycosylation close to in vivo condition, tumor cell suspensions were prepared immediately after resection (<10 min), as described previously with modification (37, 38) .
Tumor tissues (~50 mg) were pieced (< 1 mm) in 100 µl of RPMI-1640 medium containing 
GCS radioenzymatic assay
It was performed as previously described (29) . Cells were homogenized by sonication in lysis buffer (50 mM Tris-HCl, pH 7.4, 1.0 µg/ml leupeptin, 10 µg/ml aprotinin, 25 µM PMSF).
Microsomes were isolated by centrifugation (129,000 g, 60 min). The enzyme assay, containing 50 µg microsomal proteins in 0.2 ml, was performed in a shaking water bath at 37°C for 60 min.
The reaction contained a liposomal substrate composed of C 6 -Cer (1.0 mM), phosphatidylcholine 
RESULTS
Quantitation of Cer glycosylation in cells
In this study, commercially available fluorescent substrate, NBD C6-Cer was used as an acceptor for glucose conversion catalyzed by GCS. NBD C6-Cer complexed to BSA is watersoluble and has high cell-permeability. To quantitate GlcCer and Cer generated during cellular glycosylation, correlations of fluorescent intensities to the amounts of NBD C6-GlcCer and NBD C6-Cer were examined using TLC separation and spectrophotometer. A mixture of NBD C6-GlcCer and NBD C6-Cer (mol/mol) was resolved on HPTLC plates in the mobile phase Quantitation of Cer glycosylation was verified using human NCI/ADR-RE cell line that has high level of GCS (19, 28) . We found that culture cells in 1% BSA RPMI-1640 medium containing NBD C6-Cer was optimal. Cellular accumulation of NBD C6-Cer in this condition was much higher than that in cells cultured with 5% FBS medium or in cells incubated with 1%
BSA RPMI-1640 medium after trypsinization. We examined whether or not cellular GlcCer and
Cer are correlated to the amounts of NBD C6-Cer added in the medium. As shown in Fig Different from test tube assay in vitro, NBD C6-Cer, a substrate for GCS in cells is not under saturation conditions once glycosylation starts. Available cellular C6-Cer is undergoing dynamic changes, briefly depending on cell uptake and metabolism during incubation. We measured cellular GlcCer after increasing periods of incubation, to find out the optimal conditions for ceramide glycosylation. As shown in Fig. 2C and 2D, Cer uptake increased during the first 30 mins and then was decreased, whereas GlcCer production constantly increased during the first 120 mins of incubation (Fig. 2C, 2D ). After two hrs, Cer accumulation was only 43% of maximum (12.5 vs. 28.9 pmol); however, cellular GlcCer generated reached a plateau, approximately 30 pmol in cells. The GC/Cer ratios were 1.4 to 2.4 from one to two hrs of incubations. Therefore, we optimized Cer glycosylation using a 2 hr incubation of cells with NBD C6-Cer in 1% BSA RPMI-1640 medium. GlcCer/Cer ratio that consistently represents
GlcCer generated in the presence of cellular Cer has been used to evaluate GCS activity.
Validation of Cer glycosylation in cells that express different levels of GCS
In addition to NBD C6-Cer, available amounts of UDP-glucose and other factors in cells also can affect GlcCer production. To examine whether these interfere enzyme measurement, we (Fig. 4D) . The GlcCer/Cer ratios measured by cell-based TLC are similar to the results of other assays and more consistent with GCS protein levels in these cells. These data indicate that other factors have fewer effects on glycosylation of NBD C6-Cer in cells.
Determination of Cer glycosylation in tissues
After examination of Cer glycosylation in varied conditions, we found that incubation of NBD C6-Cer with freshly prepared cell suspension is a reliable approach to assess GCS enzyme in tissues. Suspending tissues has been frequently used to isolate stem cells from different tissues (37, 38) . However, it is barely tested whether tissue suspension is applicable for enzyme assay.
We pieced tumors immediately after resection and carried out glycosylation of NBD C6-Cer in these cell suspensions. It was found that NBD sphingolipid was accumulated in cells after 2 hr incubation (Fig. 5A) . Suspended tumor cells took up NBD C6-Cer and produced NBD C6-GlcCer (Fig. 5B) . Quantitative determination of these showed cellular Cer or GlcCer had a good correlation to NBD C6-Cer concentrations added in the reactions (Fig. 5C) . A correlation coefficient for cellular ceramide is 0.97 (r 2 of sigmoidal does-response with variable slope), and the accumulation rate of Cer is 1.4% under those conditions. The coefficient for produced GlcCer is 0.95 and the GCS K m in tumor of NCI/ADR-RE is 40.55 µM, which is similar to that measured in cells (38.77 µM, Fig. 2B ). This method was able to detect GlcCer generated in 1 mg of tumor tissues (not shown here). In order to verify the influence of GalCer on GlcCer assessment, we tested NBD C6-GalCer generation in tumors treated with D-threo-PDMP. We found that the intensities of C6-GalCer generated in tumor suspensions are close to the background (Fig. 6A) . D-threo-PDMP decreased GlcCer generation and reduced the GlcCer/Cer ratios to 27% (0.11 vs. 0.27 p<0.001, as compared to vehicle (Fig. 6B ), but this did not significantly affect C6-GalCer (Fig. 6A, 6B ). These data indicate tissue suspension prepared in this study is useful for GCS assessment.
Furthermore, we examined ceramide glycosylation in tumors with GCS gene manipulation.
GCS protein was overexpressed in NCI/ADR-RE/GCS tumors, as compared to NCI/ADR-RE (saline treatment, Fig. 6C, top panel). MBO-asGCS treatment suppressed GCS gene expression
and significantly decreased its protein levels in NCI-ADR-RE and SW620Ad tumor xenografts (Fig. 6C) . Assessment of NBD C6-Cer glycosylation in tumor suspensions found that the GlcCer/Cer ratios were increased to 140% (0.79 vs. 0.5, p<0.001 as compared to control) in NCI/ADR-RE/GCS tumors, and were decreased to 73% (0.367 vs. 0.50, p<0.001) in NCI/ADR-RE tumors treated with MBO-asGCS (Fig. 6D) . In SW620Ad tumors, the GlcCer/Cer ratio was decreased to 56% (0.30 vs. 0.53, p<0.001) after MBO-asGCS treatment (Fig. 6D ). These data indicate that the GlcCer/Cer ratios in these tumors are consistent with the GCS protein levels,
representing GCS activities in vivo.
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DISCUSSION
In the present study, we developed a simple and reliable method directly to quantitate ceramide glycosylation catalyzed by GCS in cells and in tissues. It provides a new approach to assess enzyme activity like GCS in vivo and to evaluate its actual roles in cell functions. Assessing activity of enzyme in cells is essential to verify the effects of enzyme on physiology and diseases; however, it is more difficult than in laboratory-made conditions. Due to the dynamic changes in uptake, substrate with high cellular permeability is a primary determinant for GCS enzymatic assay in vivo. NBD C6-Cer has been used to assay GCS activity in vitro (26, 27, 44, 45) and track Cer translocation in cells (30, 46) . In present study, NBD C6-Cer has been efficiently taken up in different human cancer cell lines and in tumors suspended. NBD C6-Cer accumulated in cells and tumor suspension at the rates of 5% (100 µM in reaction) and 1.4%
(400 µM in reaction), respectively. Cellular NBD C6-Cer is linearly correlated to these added in the reactions (r 2 = 0.99). More importantly, it sequentially provided adequate amounts of substrates for Cer glycosylation by GCS in these enzymatic reactions (Fig. 2, 5 ). The levels of GlcCer produced were linearly correlated to NBD C6-Cer concentrations added in reactions of cells (r 2 = 0.99) and tumor suspension (r 2 = 0.95) (Fig. 2) and 0.95 in tumor tissues (Fig. 5) .
These results pint out that NBD C6-Cer is a suitable substrate for Cer glycosylation in vivo and assessment of NBD C6-Cer glycosylation is an applicable approach to measure GCS activity intracellularlly.
In cells, Cer can be converted to GlcCer and GalCer in glycosylation, to sphingosine with ceramidases and to sphingomyelin with sphingomyelin synthase. Among these, the conversion of NBD C6-Cer and UDP-galactose to NBD C6-GalCer by CGT shares the same cellular processes including uptake and transporting to endoplasmic reticulum as the conversion of Cer and UDP-glucose to GlcCer. NBD C6-GalCer has a similar property as NBD C6-GlcCer, and possibly interfere the measurement of GC on TLC-spectrophotometry. C6-Cer has been used as substrate for CGT assay (40, 41) . Interestingly, we found only a few amounts of GalCer was generated either in cells or in tumors incubated with NBD C6-Cer, even when GCS was inhibited ( Fig. 4A,   4B ; Fig. 6A, 6B) . GlcCer was the dominant product in all glycosylations of NBD C6-Cer conducted either in cells or in tissue suspensions. These suggest that glycosylation of NBD C6-Cer in the condition tested herein is reliable and reproducible to assess GCS activity in vivo. A caution is needed when applying this method to assess GCS in cells and tissues that have high levels of CGT, such as glioma (47), brain and kidneys.
Previous report suggests that several other factors including endogenous UDP-glucose, ceramide subcellular localization, and co-enzymes may modulate Cer glycosylation (1). Cell glycosylation of Cer is more sophisticated and GlcCer production is the sum of series of cell biological and biochemical processes. Many factors in these processes may limit the directindication of NBD C6-GlcCer for GCS activity. This study clearly indicates that NBD C6-GlcCer generated substantially represents GCS enzyme activity, at lease in tested cells and tissues. We found that the K m value of human GCS (38.8 µM) in NCI/ADR-RE cells is higher than the rat GCS K m (14.3 µM) using NBD C6-Cer in test-tube assay (45) . In tumors generated from NCI-ADR-RE cells, the GCS K m is 40.6 µM, very close to that measured in the cells.
Using this new method, we have successful detected the GCS activities in cells and tumors that expressing GCS protein in different degrees (Fig. 3, Fig. 6 ) or in which GCS has been inhibited by D-thero-PDMP (Fig. 4A, 4B , 6A, 6B). Comparing with radioenzymatic assay or endogenous
GlcCer assessment, the GlcCer/Cer ratios (GCS activity) using this method are more close to the GCS protein levels in cells (Fig. 3, Fig. 4C, 4D ). We also found that the GlcCer/Cer ratios tested with tissue suspensions are highly corresponded to the GCS protein levels in tumor tissues (Fig.   6 ). This study indicates that applying NBD C6-Cer as a substrate for TLC-based assay can quantitatively determine GCS activity in as less as 5 x 10 4 cells and 1 mg tumor tissue.
We used Cer glycosylation by GCS as a sample exploring the possibility to assess enzyme in vivo directly. This study demonstrated that it is feasible to use suitable substrate with system to evaluate enzyme in cells and tissues. For GCS assay, introducing radioactive labeled ceramide as substrate and HPLC separation into the condition used in this study may significantly increase the sensitivity of Cer glycosylation in vivo. The cell-based fluorescent TLC developed by the present study is a simple, reproducible and direct means for GCS analysis. In addition to cell study, this method may be applicable to evaluating GCS roles in tissues, predicting drug resistance for cancer and insulin resistance for type II diabetes. Results represent the mean ± SD of three independent enzyme reactions in triplet. Results are the mean ± SD of three independent experiments. 
